A5014539718- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Neurological Complications and Syndromes
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Nail Diseases and Treatments
- Injury Epidemiology and Prevention
- Parvovirus B19 Infection Studies
- Viral-associated cancers and disorders
- Bacterial Identification and Susceptibility Testing
- Infectious Diseases and Mycology
- Mycobacterium research and diagnosis
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Antibiotics Pharmacokinetics and Efficacy
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Cardiac Arrest and Resuscitation
- Urinary Tract Infections Management
- Long-Term Effects of COVID-19
- HIV Research and Treatment
University of Wisconsin–Madison
2016-2025
UW Health University Hospital
2017-2025
UCLA Health
2018
University of Michigan
2008-2012
VA Ann Arbor Healthcare System
2009-2010
Michigan Medicine
2009
Halstead Hospital
1971
We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P<0.025) between and drug concentration was detected. Favorable responses were observed in 10/10 with concentrations above 2.05 microg/ml, while progressed 44% (n=18) below microg/ml.
The optimal treatment for respiratory syncytial virus (RSV) infection in adult immunocompromised patients is unknown. We assessed the management of RSV and other non-influenza viruses Midwestern transplant centers.A survey assessing strategies viral infections was sent to 13 centers.Multiplex polymerase chain reaction assay used diagnosis 11/12 centers. Eight 12 centers inhaled ribavirin (RBV) some patient populations. Barriers included cost, safety, lack evidence, inconvenience. Six...
Few options are available for cytomegalovirus (CMV) treatment in transplant recipients resistant, refractory, or intolerant to approved agents. Letermovir (LET) is prophylaxis hematopoietic cell (HCT) recipients, but little known about efficacy CMV infection. We conducted an observational study determine the patterns of use and outcome LET infection recipients.Patients who received were identified at 13 centers. Demographic data collected.Twenty-seven solid organ 21 HCT (one dual) from...
In this narrative medicine essay, an infectious diseases physician who is immunocompromised laments the disdain she felt while continuing to wear a mask after vaccinations allowed most people shed them.
Background: Letermovir is approved for primary prophylaxis of cytomegalovirus (CMV) in high-risk kidney transplant recipients. However, many experts suggest the drug be reserved as a second-line agent when valganciclovir not tolerated or fails. Objective: The purpose this study was to describe feasibility de novo letermovir prophylactic approach CMV and seropositive abdominal solid organ patients. Methods: Retrospective review recipients who required between June 6, 2023, 2024. evaluate...
Abstract Background Small colony variants (SCVs) of Staphylococcus aureus (SA) have significant intracellular persistence. Fluoroquinolones demonstrate activity and are often utilized to treat SCVs. Delafloxacin is a fluroquinolone with increased potency at low pH, which could lead enhanced activity. This study evaluates delafloxacin against MSSA MSRA SCV isolates.Figure 1.Illustration co-culture methods Methods Six clinical SCV-SA isolates were co-cultured human macrophages for 1 hour,...
Infective endocarditis is an uncommon manifestation of infection with Histoplasma capsulatum. The diagnosis frequently missed, and outcomes historically have been poor. We present 14 cases seen in the last decade at medical centers throughout United States. All patients were men, 10 had infected prosthetic aortic valve. One patient left atrial myxoma. Symptoms a median 7 weeks before was established. Blood cultures yielded H. capsulatum only 6 (43%) patients. antigen urine and/or serum all...
Abstract Purpose Valganciclovir (VGC) is the gold‐standard for cytomegalovirus (CMV) prophylaxis (PPX) after solid organ transplant (SOT). Letermovir (LTV) was recently approved in high‐risk kidney and has reduced myelosuppressive toxicity. Conversion from VGC to LTV may be pursued setting of leukopenia. It unknown if this strategy effective. Methods Adult patients receiving abdominal SOT were included converted between January 1, 2018 31, 2023. Primary objective describe impact conversion...
Background. Kidney transplant recipients (KTRs) are a vulnerable immunocompromised population at risk of severe COVID-19 disease and mortality after SARS-CoV-2 infection. We sought to characterize the post-infection sequelae in KTRs our center. Methods. studied all adult (with functioning allograft) who had their first episode infection between 04/2020 04/2022. Outcomes interest included factors for hospitalization, all-cause mortality, COVID-19-related allograft failure. Results. Of 979...
Incidence of primary and recurrent Clostridium difficile infection (CDI) is higher in solid-organ transplant recipients than the average hospitalized patient. Strategies for preventing CDI are limited. Prophylaxis with oral vancomycin (VPPx) may be beneficial, but there limited evidence supporting its use.To examine impact VPPx (125 mg twice daily) prevention renal (RTX) receiving high-risk broad spectrum antibiotics (BSAs).Adult RTX history CDI, receipt BSAs during a unit-specific outbreak...
Cytomegalovirus (CMV) infection in kidney transplant recipients has been anecdotally observed with concomitant or subsequent opportunistic infections (OI), but this association yet to be defined quantified.Patients who received a renal between 1/1/2005 and 6/30/2014 developed CMV were matched controls ratio of 1:2 the rates co-infection calculated within pre-specified time frames (-30 days +90 -30 +180 days). The primary outcome was composite OI rate, secondary outcomes included patient...